

1 Metastatic niche labelling reveals tissue parenchyma stem cell features

2
3 Luigi Ombrato¹, Emma Nolan¹, Ivana Kurelac^{1,4}, Antranik Mavousian², Victoria Bridgeman¹,
4 Ivonne Heinze³, Probir Chakravarty⁵, Stuart Horswell⁵, Estela Gonzalez-Gualda¹, Giulia
5 Matacchione¹, Anne Weston⁶, Joanna Kirkpatrick³, Ehab Husain⁷, Valerie Speirs⁸, Lucy
6 Collinson⁶, Alessandro Ori³, Joo-Hyeon Lee^{2*}, Ilaria Malanchi^{1*}

7
8 *1 Tumour Host Interaction laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT London; 2 Wellcome*
9 *Trust/Medical Research Council Stem Cell Institute, University of Cambridge, Tennis Court Road, Cambridge CB2*
10 *1QR, UK; 3 Proteomics of aging, Leibniz Institute on Aging, Fritz Lipmann Institute (FLI) Beutenbergstrasse 11,*
11 *07745 Jena, Germany; 4 Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna, Via Massarenti 9,*
12 *40138 Bologna, Italy; 5 Bioinformatics & Biostatistics Unit, The Francis Crick Institute, 1 Midland Road, NW1 1AT*
13 *London; 6 Electron Microscopy Unit, The Francis Crick Institute, 1 Midland Road, NW1 1AT London; 7 Department*
14 *of Pathology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, AB25 2ZN, Scotland, UK; 8 Institute of Medical*
15 *Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, Scotland, UK.*

16 **Corresponding authors: Ilaria Malanchi (Ilaria.Malanchi@crick.ac.uk) and Joo-Hyeon Lee (jhl62@cam.ac.uk).*

17
18 **To date, a direct investigation of the early cellular changes induced by metastatic cells**
19 **within the surrounding tissue is difficult to achieve. We present the strategy whereby**
20 **metastatic cancer cells release a cell-penetrating fluorescent protein taken up by**
21 **neighbouring cells, allowing spatial identification of the local metastatic cellular**
22 **environment within the whole tissue. Hence, the presence of low represented niche**
23 **cells can be detected and characterised among the bulk tissue. To highlight its**
24 **potential, we have applied this system to study the lung metastatic environment of**
25 **breast cancer. We report the unprecedented presence of cancer associated**
26 **parenchymal cells (CAPs), showing stem cell-like features, expression of lung**
27 **progenitor markers, multi-lineage differentiation potential and self-renewal activity. In**
28 **ex vivo assays, lung epithelial cells acquire a CAP-like phenotype when co-cultured**
29 **with cancer cells and support their growth. The data highlight the remarkable potential**
30 **of this method as a platform for new discoveries.**

33 Cancer cell behaviour is strongly influenced by the surrounding cells of the tumour
34 microenvironment (TME). Various cell types are known in the TME to have a significant impact
35 on cancer cell behaviour, namely mesenchymal cells such as activated fibroblasts, pericytes
36 and endothelial cells, alongside with different types of inflammatory cells¹.

37 During the early phase of metastatic growth, cancer cells generate a local tissue
38 microenvironment (metastatic niche), which is very distinct from the normal tissue structure
39 and key to support metastatic outgrowth². However, a detailed analysis of the cellular
40 composition of the metastatic niche, especially at early stages, is significantly constrained by
41 the difficulty to spatially discriminate the niche cells within the bulk of the tissue. This hampers
42 identification of those cells that might respond to early cancer cell colonization but remain less
43 represented as metastases grow bigger.

44 In this study, we present a strategy to overcome these limitations whereby metastatic cancer
45 cells mark their neighbouring cells identifying them in the tissue. We have applied this system
46 to interrogate the early metastatic environment of breast cancer in the lung. After confirming
47 that the system allows to quantitatively and qualitatively distinguish the subset of known
48 metastatic niche cells among the entire tissue, we identified lung epithelial cells as a new
49 component of metastatic TME, in which a regenerative-like program is activated. We show
50 that those epithelial cells acquire multi-lineage differentiation potential when co-cultured with
51 cancer cells and support their growth. The data support the notion that, in addition to the well
52 characterized stromal activation, a parenchymal response might contribute to creating the
53 metastatic microenvironment.

54

55 **The Cherry-niche labelling system**

56 To develop a labelling system where metastatic cancer cells directly identify their neighbouring
57 cells *in vivo*, we generated a version of a secreted monomeric Cherry red fluorescent protein
58 (mCherry) containing a modified lipo-permeable Transactivator of Transcription (TATk)
59 peptide^{3,4} (sLP-mCherry) (Figure 1a and Extended Data Figure 1a). We engineered 4T1
60 breast cancer cells to express the sLP-mCherry protein alongside a canonical cell-retained
61 Green Fluorescent Protein (GFP), which we refer to as Labelling-4T1. *In vitro*, sLP-mCherry
62 protein released by Labelling-4T1 is re-up-taken within producing cells as observed by
63 changes in the intracellular localisation of the red fluorescence (Extended Data Figure 1b, c).
64 Importantly, sLP-mCherry protein is also taken up by unlabelled cells both in co-culture (Figure
65 1b-d) and when cultured with Labelling-4T1 conditioned medium (LCM) (Extended Data
66 Figure 1d-e). Upon uptake, sLP-mCherry fluorescence has an intracellular half-life of 43h
67 (Extended Data Figure 1f) and is localized in CD63⁺ multi-lamellar bodies (lysosomal-like
68 structures), where, due to its high photostability⁵, it retains high fluorescent intensity (Extended
69 Data Figure 1g, h). LCM fractionation shows that only the soluble fraction displays labelling

70 activity, while the extracellular vesicles (EVs), a portion of which contains sLP-mCherry, do
71 not show *in vitro* labelling activity (Extended Data Figure 1i-k).
72 Critically, *in vivo*, Labelling-4T1 cells (GFP/Cherry double positive) intravenously injected into
73 syngeneic BALB/c mice to induce lung metastases, efficiently label their surrounding host
74 tissue cells (Cherry single positive), with a penetration of approximately five cell layers (Figure
75 1e⁶-g and Extended Data Figure 2a, b). This allows host cells in close proximity to cancer cells
76 to be specifically discriminated from the distal lung (GFP/Cherry double negative) using
77 fluorescent activated cell sorting (FACS) (Figure 1f). Notably, when metastases form, the
78 number of mCherry⁺ niche cells in the tissue remains proportional to the growing metastatic
79 cells (Extended Data Figure 2c). We detected no adaptive immunogenicity against sLP-
80 mCherry and the local increase of CD45⁺ immune cells within the mCherry population was
81 observed specifically as a response to cancer cells (Extended Data Figure 2d-f). Hence, the
82 *Cherry-niche* marking system (Cherry-niche) enables the spatial reconstitution of the local
83 metastatic niche within the whole tissue. This allows functional identification of labelled cells
84 (Cherry-niche cells) and their direct comparison with the remaining unlabelled tissue cells
85 within the same lung.

86

87 **Tissue spatial resolution**

88 To demonstrate the utility of Cherry-niche to specifically interrogate the local early changes
89 induced by cancer cells, we seeded 4T1-labelling cells in the lung via the tail vein. Here the
90 lung tissue distant from micro-metastases remains unperturbed by primary tumour-derived
91 systemic changes⁷. To validate the Cherry-niche strategy, we first examined known
92 components involved in metastatic niche formation. CD45⁺ immune cells are very abundant
93 within Cherry-niche and nearly exclusively derive from the myeloid lineage (CD11b⁺)
94 (Extended Data Figure 2d and 3a). Lung neutrophils are widely reported to enhance
95 metastatic growth of cancer cells^{8,9}, and were indeed detected within the Cherry-niche
96 (Extended Data Figure 3b). Since abnormalities in lung neutrophils associated with cancer are
97 broadly found¹⁰, we isolated Cherry-niche neutrophils (Ly6G⁺) and compared their proteome
98 to unlabelled neutrophils from the same lungs (Figure 2a). We found the sub-pool of Cherry-
99 niche neutrophils to have distinct features, with an increase in translational and oxidative
100 phosphorylation activities, as well as higher levels of intracellular Reactive Oxygen Species
101 (ROS) determined by FACS analysis (Figure 2b, Extended Data Figure 3c-f and
102 Supplementary File 2). To validate the functional relevance of specific niche cell features
103 identified using Cherry-niche, we developed a three-dimensional (3D) scaffold (Alvetex) co-
104 culture system, mimicking complex tissue-like cell-cell interactions. When monitoring actin-
105 GFP⁺ Mouse Mammary Tumour Virus (MMTV) Polyoma virus Middle T antigen (PyMT) breast
106 cancer cells, we found lung neutrophils to boost their growth in a ROS dependent manner

107 (Figure 2c-e and Extended Data Figure 3g, h). Collectively, these data highlight the potential
108 of Cherry-niche to detect *in vivo* changes spatially restricted to the metastatic environment.

109

110 **The non-immune Cherry-niche signature**

111 Whereas the contribution of immune cells to metastatic outgrowth has often been
112 investigated¹¹, less is known about the role of other TME cell types during metastatic nesting.
113 Notably, Cherry-niche labelling can be used to provide spatio-temporal information, by
114 applying it to different stages of metastatic progression. We generated the gene expression
115 profile of non-immune (CD45-ve) Cherry-niche cells at the time point directly preceding micro-
116 metastases as well as at an advanced metastatic stage (Figure 3a, b⁶). The majority of
117 alterations were detected at the early stage, but additional changes subsequently
118 discriminated the niche of macro-metastases (Figure 3c and Extended Data Figure 4a, b),
119 confirming the evolution of the metastatic TME over time. MetaCore dataset enrichment and
120 Gene Set Enrichment Analysis (GSEA) highlighted changes in pathways related to
121 proliferation, inflammation and tissue remodelling (Extended Data Figure 4b, c). We next
122 focused on the upregulated (>2) genes encoding for soluble factors in the niche at both time
123 points (Figure 3d, Supplementary File 3). Again, as validation of the ability of our labelling
124 system to faithfully capture the *in vivo* niche, we could find many previously reported tumour
125 promoting factors¹²⁻¹⁹. We also found Wnt1 induced protein (Wisp1), previously suggested to
126 act as an oncogene in breast cancer²⁰, to be an abundant niche factor (Figure 3d). Indeed,
127 upregulation of Wisp1 in both cancer and niche cells was detected and its pro-metastatic
128 activity was confirmed by exogenous inhibition *in vivo* (Figure 3e and Extended Data Figure
129 5a-e).

130 We next probed for the presence of previously uncharacterized niche cells, which might be
131 difficult to resolve by standard techniques due to a lower frequency. Interestingly, we found
132 pathways associated with lung epithelial cells in the metastatic niche signature (Figure 3f).
133 Micro-metastases grow embedded within the alveolar compartment of the lung, and alveolar
134 type II cells (AT2) expressing Surfactant protein C (SP-C) were found in the metastatic niche
135 (Figure 3g). Indeed, further confirming the presence of cells of parenchymal origin, using the
136 epithelial cell adhesion molecule (Epcam) marker, we found Cherry-niche epithelial cells
137 predominantly as low/mid-Epcam cells (Figure 3h, i).

138

139 **Cancer associated parenchymal cells (CAPs)**

140 We found Cherry-niche epithelial cells to have a higher proliferative activity compared to their
141 normal lung counterpart (Figure 4a). Concordantly, we found the presence of alveolar cell
142 clusters with increased proliferative activity at the metastatic borders of human breast cancer
143 lung metastases, suggesting that a lung parenchyma response to metastatic growth may

144 occur in both mouse and human (Extended Data Figure 6a-f). Cancer cells profit from the
145 presence of a lung parenchymal response, as freshly isolated Epcam⁺ cells from naïve lungs
146 supported the growth of MMTV-PyMT/actin-GFP tumour cells in our 3D scaffold co-culture
147 system (Figure 4b-d). Moreover, in line with the previous data (Figure 2c-e), the presence of
148 both lung neutrophils and epithelial cells further enhanced tumour growth (Extended Data
149 Figure 7a-d), highlighting the cellular complexity of the metastatic niche.

150 We then aimed to better define the perturbation occurring in lung epithelial cells when they
151 are in the proximity of cancer cells. To contextualize their presence among the other niche
152 cellular components, we performed single cell RNA sequencing of CD45-ve cells. tSNE
153 analysis of Cherry-niche cells identified a large stromal cluster, where different stromal cells
154 can be distinguished (Figure 4e and Extended Data Figure 8a-c). This is in agreement with
155 the various known mesenchymal cell components of TME, as well as the characterization of
156 different fibroblast subsets²¹⁻²⁴. Notably, specifically in the niche, Epcam-expressing epithelial
157 cells are distributed in two clusters distinguished by the expression of E-Cadherin (Cdh1) (Fig
158 4e). We found that only niche Epcam⁺Cdh1⁺ cells share the expression of alveolar genes²⁵
159 with unlabelled distant lung Epcam⁺ cells (Fig 4f, g). Conversely, niche Epcam⁺Cdh1⁻ cells
160 express both the Sca1 (Ly6a) and Tm4sm1 progenitor markers²⁶⁻²⁸ (Fig 4g). As validation of
161 this de-differentiated signature observed in epithelial cells in the niche, qPCR of Epcam sorted
162 Cherry-niche cells also show an overall reduction in expression of alveolar lineage markers
163 (Figure 4h). Moreover, the enrichment of Epcam⁺Sca1⁺ cells was confirmed by FACS in the
164 lung Cherry-niche of different metastatic cell types (Figure 4i and Extended Data Figure 9a-
165 c). Similarly, the presence of epithelial cells expressing another lung progenitor marker,
166 integrin β 4 (CD104)²⁹, was increased in the niche as well as in *ex vivo* co-cultures (Extended
167 Data Figure 9d-i).

168 In summary, we describe a parenchymal response to lung metastasis involving de-
169 differentiated pools of epithelial cells in the niche, which we define as cancer associated
170 parenchymal cells (CAPs).

171

172 **CAPs are activated AT2 cells**

173 To functionally characterize CAP cells, we tested their lineage differentiation potential *ex vivo*
174 using a 3D Matrigel-based organoid co-culture system²⁷ (Figure 5a). Unlabelled resident lung
175 Epcam⁺ cells are predominantly alveolar, as previously shown²⁷, and formed mainly alveolar
176 organoids when co-cultured with CD31⁺ cells (Figure 5b-d). Strikingly, Cherry-niche Epcam⁺
177 cells favoured the bronchiolar lineage and showed a remarkable capacity to generate multi-
178 lineage bronchioalveolar organoids (Figure 5d). Despite the bias in organoid formation
179 towards the bronchial lineage, there were no visible signs of Cherry labelled bronchial cells *in*

180 *vivo* (Extended Data Figure 10a). CAPs also retained high self-renewal capacity over multiple
181 passages (Figure 5e).

182 Next, we tested whether tumour cells could directly induce the CAP phenotype. When Epcam⁺
183 cells from either unlabelled distal micro-metastatic lungs or naïve lungs were co-cultured with
184 metastatic cells, they generated a higher proportion of bronchiolar and bronchioalveolar
185 organoids (Figure 5f-h and Extended Data Figure 10b, c). Similar alterations were induced by
186 cancer cells when the assay was performed using mouse lung fibroblasts (MLg cells) instead
187 of CD31⁺ cells (Extended Data Figure 10b, c).

188 Certainly, lung Epcam⁺ cells are predominantly alveolar, but they also contain epithelial
189 progenitors that could be enriched by cancer cells to generate an increased plasticity^{27,30}.
190 Therefore, we performed organoid cultures using lineage-labelled AT2 cells (Sftpc-lineage).
191 Remarkably, Sftpc-lineaged cells, which show no plasticity in co-culture with CD31⁺ cells,
192 when exposed to cancer cells generated a notable amount of multi-lineage bronchioalveolar
193 organoids, supporting the idea of a reprogramming activity driven by cancer cell-derived
194 factors *ex vivo* (Figure 5i, j). Despite the potential of cancer cells to modulate the organoid
195 formation ability of lineage-labelled club cells (Scgb1a1-lineage), only rare single Scgb1a1-
196 lineage cells were found in proximity to lung metastases (Extended Data Figure 10d-f).
197 Conversely, metastases growing in Sftpc-lineage lungs demonstrated the alveolar (AT2) origin
198 of the CAPs (Figure 5k).

199 Recently, a rare population of AT2 cells expressing *Axin2* with stem cell and repair activity
200 (AT2stem), was described in the lung alveoli³¹. While a small proportion of Axin2⁺ cells was
201 found in the unlabelled epithelial cluster, Axin2 was undetectable in the niche Epcam clusters
202 (data not shown). Therefore, even if cancer cell seeding could trigger lung injury, this
203 phenomenon does not appear to specifically maintain an Axin2⁺ AT2 population in the niche.
204 Collectively, these data show the alveolar origin of CAPs and the potential of cancer cells to
205 induce multi-lineage potential of epithelial cells *ex vivo*.

206

207 **Discussion**

208 This study proposes a novel labelling system and demonstrates its ability to resolve the host
209 tissue cellular environment spatially restricted to regions surrounding cancer cells.
210 Remarkably, we report the presence of a lung epithelial compartment within the metastatic
211 niche, which originates from Alveolar Type II cells. We define this novel TME component as
212 CAPs and describe their activated regenerative state by showing a de-differentiated signature,
213 tissue stem cell-like features, multi-lineage differentiation potential and increased self-renewal
214 activity.

215 Parenchymal cells have been previously described to trigger a tissue-wide pro-tumourigenic
216 inflammatory response to systemic primary tumour signals^{32,33}. In addition to these systemic

217 effects, here we collectively show that a regenerative-like activation in the lung parenchyma
218 occurs as a direct local response during breast cancer metastasis. This parenchymal
219 response, alongside with the stromal activation, might be important to orchestrate tumour
220 niche formation.

221 Taken together, these results consolidate Cherry-niche as a platform for new discoveries with
222 the potential to identify, isolate and functionally test tissue cells from the metastatic niche with
223 unprecedented spatial resolution.

224

225

226

227 **Online Content:** Data availability information, Methods, along with any additional Extended
228 Data display items in the online version of the paper; references unique to these sections
229 appear only in the online paper. Source Data are available in the indicated legends

230

231

232

233 **References**

- 234 1. Hanahan, D. & Coussens, L. M. Accessories to the Crime: Functions of Cells Recruited
 235 to the Tumor Microenvironment. *CCELL* **21**, 309–322 (2012).
 236 2. Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and
 237 metastasis. *Nature Medicine* **19**, 1423–1437 (2013).
 238 3. Barash, S., Wang, W. & Shi, Y. Human secretory signal peptide description by hidden
 239 Markov model and generation of a strong artificial signal peptide for secreted protein
 240 expression. *Biochemical and Biophysical Research Communications* **294**, 835–842
 241 (2002).
 242 4. Flinterman, M. *et al.* Delivery of Therapeutic Proteins as Secretable TAT Fusion
 243 Products. *Mol Ther* **17**, 334–342 (2009).
 244 5. Shaner, N. C., Steinbach, P. A. & Tsien, R. Y. A guide to choosing fluorescent proteins.
 245 *Nat Meth* **2**, 905–909 (2005).
 246 6. del Pozo Martin, Y. *et al.* Mesenchymal Cancer Cell-Stroma Crosstalk Promotes Niche
 247 Activation, Epithelial Reversion, and Metastatic Colonization. *CellReports* **22**, 2456–
 248 2469 (2015).
 249 7. Peinado, H. *et al.* Pre-metastatic niches: organ-specific homes for metastases. *Nat Rev*
 250 *Cancer* **17**, 302–317 (2017).
 251 8. Wculek, S. K. & Malanchi, I. Neutrophils support lung colonization of metastasis-initiating
 252 breast cancer cells. *Nature* **17**, 413–417 (2015).
 253 9. Coffelt, S. B., Wellenstein, M. D. & de Visser, K. E. Neutrophils in cancer: neutral no
 254 more. *Nature review cancer* **16**, 431–446 (2016).
 255 10. Singhal, S. *et al.* Origin and Role of a Subset of Tumor-Associated Neutrophils with
 256 Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer. *CCELL* **30**, 120–
 257 135 (2016).
 258 11. Blomberg, O. S., Spagnuolo, L. & de Visser, K. E. Immune regulation of metastasis:
 259 mechanistic insights and therapeutic opportunities. *Dis. Model. Mech.* **11**, dmm036236–
 260 12 (2018).
 261 12. Kessenbrock, K., Plaks, V. & Werb, Z. Matrix Metalloproteinases: Regulators of the
 262 Tumor Microenvironment. *Cell* **141**, 52–67 (2010).
 263 13. Kowanetz, M. *et al.* Granulocyte-colony stimulating factor promotes lung metastasis
 264 through mobilization of Ly6G+Ly6C+ granulocytes. *Proc. Natl. Acad. Sci. U.S.A.* **107**,
 265 21248–21255 (2010).
 266 14. Qian, B.-Z. *et al.* CCL2 recruits inflammatory monocytes to facilitate breast-tumour
 267 metastasis. *Nature review cancer* **475**, 222–225 (2011).
 268 15. Acharyya, S. *et al.* A CXCL1 Paracrine Network Links Cancer Chemoresistance and
 269 Metastasis. *Cell* **150**, 165–178 (2012).
 270 16. Oskarsson, T. *et al.* Breast cancer cells produce tenascin C as a metastatic niche
 271 component to colonize the lungs. *Nature Medicine* **17**, 867–874 (2011).
 272 17. Erez, N. Opening LOX to metastasis. *Nature* **522**, 41–42 (2015).
 273 18. Onnis, B., Fer, N., Rapisarda, A., Perez, V. S. & Melillo, G. Autocrine production of IL-
 274 11 mediates tumorigenicity in hypoxic cancer cells. *J. Clin. Invest.* **123**, 1615–1629
 275 (2013).
 276 19. Malanchi, I. *et al.* Interactions between cancer stem cells and their niche govern
 277 metastatic colonization. *Nature* **481**, 85–89 (2011).
 278 20. Su, F., Overholtzer, M., Besser, D. & Levine, A. J. WISP-1 attenuates p53-mediated
 279 apoptosis in response to DNA damage through activation of the Akt kinase. *Genes Dev.*
 280 **16**, 46–57 (2002).
 281 21. Costa, A. *et al.* Fibroblast Heterogeneity and Immunosuppressive Environment in
 282 Human Breast Cancer. *CCELL* **33**, 463–479.e10 (2018).
 283 22. Karnoub, A. E. *et al.* Mesenchymal stem cells within tumour stroma promote breast
 284 cancer metastasis. *Nature* **449**, 557–563 (2007).
 285 23. Hosaka, K. *et al.* Pericyte–fibroblast transition promotes tumor growth and metastasis.
 286 *Proc. Natl. Acad. Sci. U.S.A.* **113**, E5618–E5627 (2016).

- 287 24. Murgai, M. *et al.* KLF4-dependent perivascular cell plasticity mediates pre-metastatic
288 niche formation and metastasis. *Nature Medicine* **23**, 1176–1190 (2017).
289 25. Treutlein, B. *et al.* Reconstructing lineage hierarchies of the distal lung epithelium using
290 single-cell RNA-seq. *Nature* **509**, 371–375 (2014).
291 26. Kim, C. F. B. *et al.* Identification of Bronchioalveolar Stem Cells in Normal Lung and
292 Lung Cancer. *Cell* **121**, 823–835 (2005).
293 27. Lee, J.-H. *et al.* Lung Stem Cell Differentiation in Mice Directed by Endothelial Cells via
294 a BMP4-NFATc1-Thrombospondin-1 Axis. *Cell* **156**, 440–455 (2014).
295 28. Zacharias, W. J. *et al.* Regeneration of the lung alveolus by an evolutionarily conserved
296 epithelial progenitor. *Nature* **555**, 251–255 (2018).
297 29. Chapman, H. A. *et al.* Integrin $\alpha6\beta4$ identifies an adult distal lung epithelial population
298 with regenerative potential in mice. *J. Clin. Invest.* **121**, 2855–2862 (2011).
299 30. McQualter, J. L., Yuen, K., Williams, B. & Bertoncello, I. Evidence of an epithelial
300 stem/progenitor cell hierarchy in the adult mouse lung. *Proc Natl Acad Sci USA* **107**,
301 1414–1419 (2010).
302 31. Nabhan, A. N., Brownfield, D. G., Harbury, P. B., Krasnow, M. A. & Desai, T. J. Single-
303 cell Wnt signaling niches maintain stemness of alveolar type 2 cells. *Science* **359**, 1118–
304 1123 (2018).
305 32. Liu, Y. *et al.* Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by
306 Activating Alveolar Epithelial TLR3 to Recruit Neutrophils. *CCELL* **30**, 243–256 (2016).
307 33. Lee, J. W. *et al.* Hepatocytes direct the formation of a pro-metastatic niche in the liver.
308 *Nature* **567**, 249–252 (2019).
309

310

311

312 Main Figures Legends

313

314 **Figure 1 - Cherry-niche labelling strategy.**

315 **a**, Labelling design. **b-c**, Representative FACS plots of (b) naïve 4T1 cells alone or (c) co-
316 cultured with Labelling-4T1. **d**, fluorescence image from co-culture (scale bar 10 μ m). Data
317 representative from 2 independent experiments (b-d). **e-g**, *In vivo* labelling: (e) experimental
318 scheme⁶; (f) representative FACS plot of a metastatic lung, n=50 mice. (g) representative
319 images of Labelling-4T1 metastasis immuno-fluorescence staining (IF) (n=8 mice): cancer
320 cells anti-GFP (green) and anti-Cherry (red), niche cells (Cherry only). DAPI (blue). Scale
321 bars: main 20 μ m, inset 10 μ m. For gating strategy see Supplementary File 1.

322

323 **Figure 2 - Cherry-niche allows detection of niche neutrophils.**

324 **a,b**, Proteomic analysis of Ly6G⁺ FACS-sorted cells: (a) all differentially detected proteins and
325 (b) oxidative phosphorylation associated proteins. **c-e**, 3D co-culture of MMTV-PyMT-GFP⁺
326 cancer cells and Ly6G⁺ MACS-sorted cells with or without the ROS inhibitor TEMPO: (c) co-
327 culture scheme; (d) GFP signal quantification (n=3 independent experiments, each with 3 to
328 10 technical replicates). Data normalised to cancer cell growth and represented as mean
329 \pm SEM. Statistical analysis on biological replicates by Two-way ANOVA; (e) representative
330 images from 3 independent experiments (day 6, scale bar 400 μ m). See Source Data.

331

332 **Figure 3 - Cherry-niche identifies epithelial component of metastatic TME.**

333 **a**, Schematic of metastatic progression using labelling-4T1 cells⁶. **b**, Experimental design for
334 RNA-seq⁶. **c**, Principle Component Analysis (PCA) diagram of CD45⁻Ter119⁻ cell signatures
335 from metastatic lungs at early (n=3, 10 mice each) and late (n=3, 5 mice each) time points. **d**,
336 Venn diagram of differentially expressed genes in Cherry-niche from RNA-seq and selected
337 factors common at early and late stages. **e**, Anti-Wisp1 blocking antibody treatment *in vivo*
338 (n=10, from two independent experiments; data shown on a Tukey plot: box from the 25th to
339 75th percentiles, the bar is the median and the whiskers from smallest to largest value). **f**,
340 GSEA correlation from RNA-seq data comparing early (n=3) or late (n=3) Cherry+ samples vs
341 their respective Cherry-controls. **g**, Representative IF image of lung tissue (n=3 mice):
342 mCherry-labelled micro-metastasis (red), Surfactant protein C (SP-C) (white) and DAPI (blue).
343 Scale bars: main 100 μ m, inset 10 μ m (white arrows: mCherry labelled SP-C⁺ cells). **h**, Epcam⁺
344 cell frequency on Lin⁻(CD45⁻CD31⁻Ter119⁻) cells in distal lung (Ch⁻) and Cherry-niche (Ch⁺)
345 estimated by FACS (n=13). **i**, Representative FACS plots from (h). Statistical analysis by
346 unpaired two-tailed t-test with Welch's correction (e), weighted Kolmogorov–Smirnov-like

347 statistic with Benjamini-Hochberg correction (f) and paired two-tailed t-test (h). See Source
348 Data.

349

350 **Figure 4 - Metastatic niche lung epithelial cells display progenitor phenotype.**

351 **a**, Scatter plot of Epcam⁺ cell proliferation by Ki67 staining on FACS-sorted cells (n=7 from
352 independent sorts). **b-d**, MMTV-PyMT-GFP⁺ cancer cell growth in 3D co-culture with MACS-
353 sorted Epcam⁺ cells: (b) co-culture scheme, (c) representative images from 4 independent
354 experiments (day 6, scale bar 400µm), (d) GFP signal quantification (n=4, each with 3
355 technical replicates, statistical analysis on biological replicates). Data normalised to cancer
356 cell growth. **e-g**, scRNA-seq analysis: tSNE plots of CD45⁻ cells from (e) Cherry-niche
357 (n=1473) or (f) distal lung (n=1996); (g) (right) heatmap of niche Epcam⁺ cells; ordered genes
358 in rows and hierarchically clustered cells in columns; (left) table shows established lineage
359 markers (bold) and putative alveolar markers²⁵ (*). **h** qRT-PCR analysis of Epcam⁺ FACS-
360 sorted cells (n=9 Sftpc, Aqp5; n=8 Sftpb, Abca3, Pdpn, Ager, Vim, Ecad; n=7 Krt6, Ncad; n=4
361 Snail, n=3 Twist). Data represented as fold change to Cherry⁻ Lung Epcam cells (Statistical
362 analysis on the DCt values). **i**, Epcam⁺Sca1⁺ cell frequency on Lin⁻(CD45⁻CD31⁻Ter119⁻) cells
363 by FACS (n=13). Statistical analysis by paired two-tailed t-test (a, h, i), one sample two-tailed
364 t-test (d). Data represented as mean ±SEM. See Source Data.

365

366 **Figure 5 - CAPs show multi-lineage differentiation potential.**

367 **a-e**, Lung organoids: (a) co-culture scheme; (b) representative bright-field images (scale bar
368 100µm); (c) representative IF of organoid sections stained with the indicated markers (scale
369 bar 50µm); (d) quantification; (e) organoid formation efficiency over passages. **f-h**, Lung
370 organoids with or without Labelling-4T1: (f) co-culture scheme, (g) representative bright-field
371 images (scale bar 100µm) and (h) quantification. **i, j**, Lung organoids with Sftpc-CreERT2
372 lineage cells with or without 4T1-GFP: (i) quantification and (j) representative bright-field
373 images, scale bar 150µm. Images are representative of six (b, c, g) and three (j) organoid
374 cultures. Data generated from independent sorts (d, h, i) and represented as cumulative
375 percentage using the mean ±SD of three co-cultures per sorting. **k**, Representative staining
376 of lineage cells in metastatic lungs from Sftpc-CreERT2 mice injected with cancer cells, either
377 E0771 (n=3; scale bar 50µm) or MMTV-PyMT (n=3; scale bar 100µm). Statistical analysis by
378 unpaired two-tailed t-test (d, e, h) and one sample two-tailed t-test (i), on original non-
379 cumulative values (see Source Data).

380

381

382

383

384 **Methods (online)**

385

386 **Statistical Analysis**

387 Statistical analyses were performed using Prism software (version 7.0c, GraphPad Software,
388 USA). P values were obtained from two-tailed Student t-tests with paired or unpaired
389 adjustment. When needed, unpaired t-test were adjusted using Welch's correction for unequal
390 variance. In one instance (Fig. 4i) data in one of the groups did not pass D'Agostino & Pearson
391 normality test, therefore a Wilcoxon matched-pairs signed rank test was performed. Single-
392 sample tests were also used for comparisons of co-cultured cancer cell growth on scaffolds
393 to the normalized value of cancer cells alone. For comparisons between two scaffold
394 conditions of growth over time or to perform multiple analysis between experimental groups,
395 Two-way ANOVA was used.

396

397 **Mouse strains**

398 All mice used are available from Jackson Laboratory. MMTV-PyMT mice³⁴ are on FVB and
399 C57BL/6 background, actin-GFP³⁵ mice and Rag1KO are on FVB background (gift from J.
400 Huelsken laboratory (EPFL, Lausanne, Switzerland)). *Sftpc-CreERT2*³⁶, *Rosa26R-YFP*³⁷
401 (*Sftpc-CreERT2;R26R-YFP*) are on a C57BL/6 background. Balb/cj mice and the above-
402 mentioned lines were bred and maintained under specific-pathogen-free conditions by The
403 Francis Crick Biological Research Facility and female mice were used between 6 to 10 weeks
404 of age. Breeding and all animal procedures were performed at the Francis Crick in accordance
405 with UK Home Office regulations under project license P83B37B3C.

406 For *ex-vivo* organoid lineage tracing experiments, *Scgb1a1-CreERT2* and *Rosa26R-fGFP*³⁸,
407 *Sftpc-CreERT2* (*Sftpc-CreERT2;R26R-fGFP* and *Scgb1a1-CreERT2;R26R-fGFP*) mice on a
408 C57BL/6 background were bred and maintained under specific-pathogen-free conditions at
409 the Gurdon Institute of University of Cambridge in accordance with UK Home Office project
410 licence PC7F8AE82.

411

412 **Tamoxifen administration**

413 Tamoxifen (Merck Sigma-Aldrich, Germany) was dissolved in Mazola corn oil (Merck Sigma-
414 Aldrich, Germany) in a 20mg/ml stock solution. Two doses of tamoxifen (0.2mg/g body weight)
415 were given via oral gavage every other day and lung tissues were collected two days after
416 tamoxifen administration to isolate cells for lung organoids. For *in vivo* lineage tracing three
417 doses of tamoxifen (0.2mg/g body weight) were given via oral gavage over consecutive days
418 and mice were injected two weeks later.

419

420 **Cells**

421 MLg cells (murine normal lung fibroblasts) were purchased from ATCC (USA). CAF (cancer
422 associated fibroblasts) isolated from MMTV-PyMT tumours and human normal fibroblast
423 (hNLF) were a gift from E.Sahai. MMTV-PyMT cells were isolated from MMTV-PyMT tumours
424 as previously described¹⁹. All other cell lines were provided the Cell Services Unit of The
425 Francis Crick Institute. All cell lines were authenticated and mycoplasma tested by the Cell
426 Services Unit of The Francis Crick Institute. MMTV-PyMT cells were cultured on collagen
427 solution coated dishes in MEM medium (DMEM/F12 (ThermoFisher Scientific, USA) with 2%
428 fetal bovine serum (FBS; Labtech, UK), 100U/ml penicillin-streptomycin (ThermoFisher
429 Scientific, USA), 20ng/ml EGF (ThermoFisher Scientific, USA) and 10µg/ml insulin (Merck
430 Sigma-Aldrich, Germany)). Collagen solution is made by 30µg/ml PureCol collagen
431 (Advanced Biomatrix, USA), 0.1% bovine serum albumin (BSA), 20mM HEPES in HBSS
432 (ThermoFisher Scientific, USA). HC11 cells were cultured in RPMI (ThermoFisher Scientific,
433 USA) supplemented with 10% FBS, 100U/ml penicillin-streptomycin, 10ng/ml EGF
434 (ThermoFisher Scientific, USA) and 5µg/ml insulin. All other cell lines were cultured in DMEM
435 (ThermoFisher Scientific, USA) supplemented with 10% FBS and 100U/ml penicillin-
436 streptomycin. All cells were cultured at 37°C and 5% CO₂.

437

438 **Human Samples**

439 Human pulmonary breast cancer metastases from independent patients were obtained from
440 the Grampian Biorepository, Aberdeen Royal Infirmary (REC approval: 16/NS/0055). Four
441 samples were stained by Immunohistochemistry and Immunofluorescence and epithelial cells
442 proliferation was quantified.

443 Information about the human samples used can be found in Supplementary File 5.

444

445 **Labelling system**

446 A soluble peptide (SP)³ and a modified TAT peptide⁴ were cloned upstream of the mCherry
447 cDNA, under the control of a mouse PGK promoter (sLP-Cherry). The sLP-Cherry sequence
448 was cloned into a pRRL lentiviral backbone. 4T1, Renca, CT26 and HC11 cells were stably
449 infected with sLP-Cherry and pLentiGFP lentiviral particles and subsequently sorted to isolate
450 Cherry⁺GFP⁺ cells.

451

452 **Induction of experimental metastases**

453 Procedures were performed at the Francis Crick in accordance with UK Home Office
454 regulations under project license P83B37B3C. Cancer cells were injected intravenously to
455 generate metastasis in the lung: 4T1 (1,000,000 cells), Renca (500,000 cells), CT26 (200,000
456 cells) were re-suspended in 100µl PBS and tail-vein injected in Balb/cJ mice. Mice were

457 sacrificed on the basis of a time period rather than based on their clinical signs. Therefore, the
458 experimental end point (time controlled, seven days unless otherwise specified), most likely
459 occurred before a humane end point (as determined by deterioration of health conditions). All
460 animals were monitored daily for unexpected clinical signs following the P83B37B3C licence
461 guidelines and the principles set out in the NCRI Guidelines for the Welfare and Use of
462 Animals in Cancer Research (UK). Deterioration of health conditions such as reduction in food
463 and water consumption and changes on the animal's general appearance or weight loss of
464 10% over a 24hr period would result in animals being sacrificed prior to the experimental end
465 point.

466

467 ***In vivo* lineage tracing experiments**

468 *Sftpc-CreERT2* and *Scgb1a1-CreERT2* mice on C57BL/6 background were tail-vein injected
469 either with 175,000 MMTV-PyMT C57BL/6 cells and lungs collected 4 weeks later or with
470 700,000 E0771 cells and lungs collected 12 days later.

471

472 **Tissue digestion for cell isolation or analysis**

473 Lung tissues were dissociated as previously described¹⁹. Briefly, lungs were removed at day
474 7 after tumour cell injection (unless otherwise specified), minced manually and then digested
475 for 30 min in a shaker at 37°C with a mixture of DNase I (Merck Sigma-Aldrich, Germany) and
476 Liberase TM and TH (Roche Diagnostics, Switzerland) in HBSS solution. Samples were then
477 washed, passed through a 100µm filter and incubated in Red Blood Cell Lysis buffer (Miltenyi
478 Biotec, Germany) for 3-5 min at room temperature. After a wash with MACS buffer (0.5% BSA
479 and 250mM EDTA in PBS), samples were passed through a 40µm filter and a 20µm strainer-
480 capped flow cytometry tube to generate a single cell suspension to use for flow cytometric
481 analysis or further purification.

482

483 **FACS analysis and cell sorting**

484 Prepared single-cell suspensions of mouse lung tissues and *in vitro* cell lines were incubated
485 with mouse FcR Blocking Reagent (Miltenyi Biotec, Germany) for 10 min at 4°C followed by
486 an incubation with a mix of pre-labelled antibodies (antibody information is provided in
487 Supplementary file 4) for 30 min at 4°C. After two washes with MACS buffer, dead cells were
488 stained with 4',6-diamidino-2-phenylindole (DAPI). Flow cytometry analyses were carried out
489 on a BD LSR-Fortessa (BD Biosciences, USA) and FlowJo 10.4.2 (FlowJO, LCC 2006-2018,
490 USA) was used for further analysis. All cell-sorting experiments were carried out on a BD Influx
491 cell sorter (BD Biosciences, USA).

492

493 **Tissue digestion and FACS analysis in *ex-vivo* lineage tracing experiments**

494 Lung tissues were dissociated with a collagenase/dispase solution as previously described²⁷.
495 Briefly, after lungs were cleared by perfusion with cold PBS through the right ventricle, 2ml of
496 dispase (50U/ml, BD Biosciences, USA) was instilled into the lungs through the trachea until
497 the lungs inflated, followed by instillation of 1% low melting agarose (Bio-Rad Laboratories,
498 USA) through the trachea to prevent leakage of dispase. Each lobe was dissected and minced
499 into small pieces in a conical tube containing 3ml of PBS, 60µL of collagenase/dispase
500 (Roche, Switzerland), and 7.5µL of 1% DNase I (Merck Sigma-Aldrich, Germany) followed by
501 rotating incubation for 45 min at 37°C. The cells were then filtered sequentially through 100-
502 and 40-µm strainers and centrifuged at 1000rpm for 5 min at 4°C. The cell pellet was
503 resuspended in 1ml of ACK lysis buffer (0.15M NH₄Cl, 10mM KHCO₃, 0.1mM EDTA) and
504 lysed for 90 s at room temperature. 6ml basic F12 media (ThermoFisher Scientific, USA) was
505 added and 500µl of FBS (Fisher Scientific, USA) was slowly added in the bottom of tube. Cells
506 were centrifuged at 1000 rpm for 5 min at 4°C. The cell pellet was resuspended in PF10 buffer
507 (PBS with 10% FBS) for further staining. The antibodies used were as follows: CD45 (30-F11)-
508 APC (BD Biosciences, USA), CD31 (MEC13.3)-APC (BD Biosciences, USA), and EpCAM
509 (G8.8)-PE-Cy7 (BioLegend, USA). For antibody list see Supplementary file 4. MOFLO system
510 (Beckman Coulter, USA) was used for the sorting at Wellcome-MRC Stem Cell Institute Flow
511 Cytometry Facility.

512

513 **Lung organoid assay**

514 Lung organoid co-culture assays were previously reported^{27,39}. Briefly, freshly sorted epithelial
515 cells (Epcam⁺CD45⁻CD31⁻Ter119⁻GFP⁻) from either the metastatic niche or the distal lung
516 were resuspended in 3D basic media (DMEM/F12, supplemented with 10% FBS,
517 penicillin/streptomycin, 1mM HEPES, and insulin/transferrin/selenium (ITS) (Merck Sigma-
518 Aldrich, Germany), and mixed with MACS-sorted CD31⁺ lung stromal cells or MLg cells
519 followed by resuspension in growth factor-reduced (GFR) Matrigel (BD Biosciences, USA) at
520 a ratio of 1:1. 100µl of mixture was then placed in a 24-well transwell insert with a 0.4µm pore
521 (Corning, USA). 1-2.5 x10³ distal lung or niche epithelial cells and 25,000 CD31⁺ or MLg cells
522 were seeded in each insert. 500µl of 3D basic media was placed in the lower chamber and
523 media was changed every other day. In addition, freshly sorted lineage-labelled Scgb1a1⁺
524 club cells or Sftpc⁺ AT2 cells were resuspended in 3D basic media followed by mixing with
525 GFR matrigel retaining CD31⁺ stromal cells as described above. For co-culture of lung
526 epithelial cells with tumour cells, a mixture of 1-2.5 x10³ distal lung epithelial cells and 25,000
527 CD31⁺ cells in Matrigel was placed in the transwell insert, and 2,000 tumour cells FACS-sorted
528 from metastatic lungs were seeded in the lower chamber. Plates were scored for colony
529 number after 14 days. Organoid-forming efficiency was calculated as number of organoids
530 formed/number of cells plated per well as a percentage. Quantification of distinct types of

531 differentiated organoids was performed by scoring the organoids expressing Sox2 or SP-
532 C/Hopx by IF staining from at least five step sections (20µm apart) per individual well. Bright-
533 field images were acquired after 14 days using an EVOS microscope (ThermoFisher
534 Scientific, USA).

535

536 **3D Cell culture**

537 Primary MMTV-PyMT actin-GFP cells were seeded at a density of 5,000 cells/well in a
538 collagen solution coated Alvetex Scaffold 96-well plate (ReproCELL, Europe). The following
539 day, Ly6G⁺ lung cells and/or Epcam⁺ lung epithelial cells were MACS sorted and seeded on
540 top of the cancer cells at a density of 50,000 cells per well. In selected experiments, wells
541 were supplemented with 4-Hydroxy-TEMPO (200µM, Merck Sigma-Aldrich, Germany) or
542 mouse anti-Wisp1 (250ng/ml, MAB1680, R&D, USA). The growth of GFP⁺ cells was monitored
543 daily for 6 days using the SteREO Lumar.V12 stereomicroscope (Zeiss, Germany), and
544 images were quantified using ImageJ (NIH, USA). For quantification, the Li's Minimum Cross
545 Entropy thresholding algorithm was performed on the stacked images.

546 For the CD104 staining experiment, Epcam⁺ lung cells were harvested from mouse lung tissue
547 via MACS sorting and seeded at a density of 1,500,000 cells per well on collagen solution
548 coated Alvetex Scaffold 12-well inserts. After 48 h, MMTV-PyMT actin-GFP cells were seeded
549 on top of the Epcam⁺ cells at a density of 2,000 cells per scaffold insert.

550

551 **Immunofluorescence and immunohistochemistry**

552 Mouse lungs were fixed in 4% PFA in PBS for 24 h and embedded in paraffin blocks. 4µm
553 thick tissue sections were cut, deparaffinised and rehydrated using standard methods. After
554 heat-mediated antigen retrieval in citrate buffer (unless stated otherwise), sections were
555 blocked with a solution of 1% BSA, 10% Donkey serum in PBS. For antibody list see
556 Supplementary file 4.

557 ***mCherry and GFP staining.*** An overnight incubation at 4°C with goat anti-GFP and rabbit
558 anti-mCherry antibodies was followed by 1 h incubation at room temperature with anti-goat
559 AlexaFluor 488 and anti-rabbit AlexaFluor 555 (both secondary antibodies were purchased
560 from ThermoFisher Scientific (USA) and used at 1:400). Next, the slides were incubated with
561 Sudan Black B for 20 min and mounted with Vectashield Mounting Medium with DAPI (Vector
562 Laboratories, USA).

563 ***Lineage staining.*** An overnight incubation at 4°C with goat anti-GFP antibody was followed
564 by 45 min incubation at room temperature with secondary biotinylated-conjugated antibodies.
565 Next, the VECTASTAIN Elite ABC kit (Vector Laboratories, USA) was used according to the
566 manufacturer's instructions. The visualization of cell nuclei was performed with hematoxylin

567 and analysis employed the Nikon Eclipse 90i light microscope and NIS-elements software
568 (Nikon, Japan).

569 **WISP1 staining.** An overnight incubation at 4°C with goat anti-GFP and rabbit anti-WISP1
570 antibodies was followed by 30 min incubation at room temperature with anti-goat AlexaFluor
571 488 and anti-rabbit AlexaFluor 555 (both secondary antibodies were purchased from
572 ThermoFisher Scientific (USA) and used at 1:500). Next, the slides were incubated with Sudan
573 Black B for 20 minutes and mounted with Vectashield Mounting Medium with DAPI (Vector
574 Laboratories, USA).

575 **Ki67 staining.** Epcam⁺CD45⁻CD31⁻Ter119⁻GFP⁻ cells were sorted from lung suspensions,
576 plated on poly-lysine glass coverslips for 15 min at room temperature and fixed in 4% PFA in
577 PBS for 10 min. After fixation, cells were permeabilized with 0.1% Triton-X-100 in PBS for 5
578 min and incubated with a blocking solution (1% BSA, 10% goat serum, 0.3M glycine, 0.1%
579 Tween in PBS) for 1 h at room temperature. Next, cells were incubated overnight with an anti-
580 mouse Ki67 antibody diluted in blocking solution followed by a 1 h incubation with a goat anti-
581 rabbit AlexaFluor 488 (1:500, ThermoFisher Scientific (USA)). Finally, cells were mounted with
582 Vectashield Mounting Medium with DAPI for imaging.

583 **E-cadherin staining.** CD49f⁺CD104⁺CD45⁻CD31⁻Ter119⁻GFP⁻ cells were sorted from lung
584 suspensions, cytopun on glass slides and fixed in 4% PFA in PBS for 10 min. Next, cells
585 were permeabilized with 0.5% TritonX-100 for 30 min and incubated in blocking solution (4%
586 BSA, 0.05% Tween20 in PBS) for 45 min at room temperature. Then, cells were incubated
587 with a rat anti-E-cadherin antibody in blocking solution overnight at 4°C followed by an
588 incubation with a goat anti-rat AlexaFluor 647 (1:500, ThermoFisher Scientific (USA)). Finally,
589 cells were mounted with Vectashield Mounting Medium with DAPI for imaging.

590 **CD104 staining.** Epcam⁺ cells were MACS sorted and plated on Alvetex scaffold inserts as
591 described above. 7 days after plating the whole scaffold was collected, washed with PBS and
592 incubated in blocking solution (10% goat serum in PBS) for 1 h at room temperature. Next,
593 the samples were incubated with a conjugated anti-CD104-eFluor660 antibody (1:100 in PBS
594 with 1:10 FcR blocking (Miltenyi Biotec, Germany)) for 1 h at room temperature. Then, the
595 samples were fixed with 4% PFA in PBS for 10 min and mounted with Vectashield Mounting
596 Medium with DAPI. Pictures were captured with the Axio Scan.Z1 slide scanner (Zeiss,
597 Germany).

598 **Lung organoid staining.** Cultured organoids were fixed with 4% PFA in PBS for 2-4 h at
599 room temperature followed by immobilization with Histogel (ThermoFisher Scientific, USA) for
600 paraffin embedding. At least five step sections (20µm apart) per individual well were stained.
601 Fluorescence images were acquired using a confocal microscope Leica TCS SP5 (Leica
602 Microsystems, Germany). All the images were further processed with Fiji software.

603 **TTF1 and Ki67 co-staining.** Target retrieval solution pH9 (Agilent DAKO, USA) was used as
604 antigen retrieval. For histology, 1h incubation at room temperature with mouse anti-TTF1 was
605 followed by 45 min incubation at room temperature with secondary biotinylated-conjugated
606 antibodies. Next, the VECTASTAIN Elite ABC kit (Vector Laboratories, USA) was used
607 according to the manufacturer's instructions. The visualization of cell nuclei was performed
608 with hematoxylin and analysis employed the Nikon Eclipse 90i light microscope and NIS-
609 elements software (Nikon, Japan). For immune-fluorescence, 1h incubation at room
610 temperature with mouse anti-TTF1 and rabbit anti-Ki67 was followed by 45 min incubation at
611 room temperature with anti-mouse AlexaFluor 555 and anti-rabbit AlexaFluor 488 (both
612 secondary antibodies were purchased from ThermoFisher Scientific (USA) and used at
613 1:250). Next, the slides were incubated with Sudan Black B for 20 min and mounted with
614 Vectashield Mounting Medium with DAPI (Vector Laboratories, USA).
615 All pictures were captured with either a Zeiss Upright710 confocal microscope or a Zeiss
616 Upright780 confocal microscope unless differently stated.

617

618 **Quantitative real time PCR**

619 RNA preparation was performed using the MagMax-96 Total RNA Isolation Kit (ThermoFisher
620 Scientific, USA). cDNA synthesis was performed using a SuperScript III First-Strand Synthesis
621 System (ThermoFisher Scientific, USA), according to the manufacturer's protocol.
622 Quantitative real-time PCR samples were prepared with 50-100ng total cDNA for each PCR
623 reaction. The PCR, data collection and data analysis were performed on a 7500 FAST Real-
624 Time PCR System (ThermoFisher Scientific, USA). GAPDH was used as internal expression
625 reference. List of primers used can be found in Supplementary File 4.

626

627 **Anti-Wisp1 treatment *in vivo***

628 BALB/cJ female mice (6-8 weeks old) were administered with anti-Wisp1 (5µg AF1680 and
629 5µg MAB1680, R&D, USA) or a control-IgG antibody via an intra-tracheal injection
630 (50µl/mouse). The following day, mice were intravenously injected with 250,000 4T1 cells.
631 Anti-Wisp1/control-IgG treatment was repeated daily, via a second intra-tracheal injection on
632 day 4, and intra-peritoneal injections on days 2,3,5 and 6. Mice were harvested 7 days after
633 the first treatment and lungs were embedded, cut and H&E stained. The lung metastatic
634 burden was assessed by counting number of metastases on four levels (100µm interval) from
635 two lung lobes (n=10 per group).

636

637 **EdU *in vitro* proliferation assay**

638 MMTV-PyMT actin-GFP cells were seeded at a density of 10,000 cells per well into collagen
639 solution coated 6-well plates. The following day, Ly6G⁺ lung cells and/or Epcam⁺ lung cells

640 were isolated via MACS sorting and added to the wells at a density of 100,000 cells/well. After
641 60h, wells were supplemented with 20 μ M EdU (5-ethynyl-2'-deoxyuridine). Cells were
642 harvested 6h later, and EdU incorporation was assessed using the Click-iT Plus EdU Flow
643 Cytometry Assay Kit (ThermoFisher Scientific, USA), according to the manufacturer's
644 instructions. Sample data were acquired on a BD LSR-Fortessa flow cytometer and analysed
645 using FlowJo 10 software.

646

647 **Conditioned media preparation and vesicle isolation**

648 4T1-sLP-mCherry-GFP cells (Labelling-4T1) were plated on 10cm petri dishes. When cells
649 were 80% confluent, 10ml of DMEM with 10% FCS was added to be conditioned for 48 h. The
650 conditioned media preparation and vesicles isolation were performed as previously
651 described⁴⁰. Briefly, the media was collected and spun at 300g for 10 min. Next, the
652 supernatant was collected and spun at 2,000g for 10 min. The supernatant after this second
653 centrifugation was collected and used as conditioned media. For vesicle isolation, the
654 conditioned media was subsequently ultra-centrifuged at 10,000g for 30 min and at 100,000g
655 for 70 min. The vesicle pellet at this stage was washed with PBS, spun at 100,000g for 70 min
656 and resuspended again in PBS for *in vitro* uptake experiments.

657

658 **ImageStream analysis**

659 Image stream analyses were carried out on an ImageStream Mark X II Imaging Flow
660 Cytometer (Amnis Merck, USA). The acquired data were analysed using IDEA software
661 (Amnis Merck, USA).

662

663 **Electron Microscopy (EM)**

664 Experiments were performed on glass bottom dishes with a numbered grid (MatTek, USA) to
665 enable subsequent location of the same cell imaged by confocal microscopy. After confocal
666 imaging, cells were fixed in 8% formaldehyde in 0.1M phosphate buffer (pH 7.4) added in
667 equal quantities to cell media for 15 min and then further fixed in 2.5% glutaraldehyde and 4%
668 formaldehyde in 0.1M phosphate buffer (pH 7.4) for 1 h and then processed using the National
669 Center for Microscopy and Imaging Research (NCMIR) protocol (Deerinck, T.J., et al., NCMIR
670 methods for 3D EM: a new protocol for preparation of biological specimens for serial block
671 face scanning electron microscopy. National Center for Microscopy and Imaging Research
672 (2010) (available from <https://ncmir.ucsd.edu/sbem-protocol>)).

673 For transmission electron microscopy (TEM), 70nm serial sections were cut using a UC6
674 ultramicrotome (Leica Microsystems, Germany) and collected on formvar-coated slot grids.
675 No post-staining was required due to the density of metal deposited using the NCMIR protocol.

676 Images were acquired using a 120 kV Tecnai G2 Spirit TEM (FEI Company ThermoFisher
677 Scientific, USA) and an Orius CCD camera (Gatan, USA).

678

679 **RNA sequencing sample preparation**

680 **Bulk RNA sequencing:** CD45⁻Ter119⁻ (CD45-ve) cells were sorted from single cell
681 suspensions of metastatic lungs stained with anti-mouse CD45 and Ter119 antibodies and
682 DAPI. RNA isolation was performed using the MagMax-96 Total RNA Isolation Kit
683 (ThermoFisher Scientific, USA) that allows high quality RNA extraction from samples with low
684 cell numbers (<10,000 cells). RNA quality for each sample was assessed using the Agilent
685 RNA 6000 Pico Kit (Agilent Technologies, USA). RNA was amplified and analysed at the Barts
686 and London Genome Centre.

687 **Single cell RNA sequencing:** CD45⁻Ter119⁻ cells were sorted from single cell suspensions
688 of metastatic lungs stained with anti-mouse CD45 and Ter119 antibodies and DAPI. Library
689 generation for 10× Genomics were performed following the Chromium Single Cell 3' Reagents
690 Kits (10X Genomics, USA) and sequenced on an Hiseq4000 (Illumina, USA), to achieve an
691 average of 50,000 reads per cell.

692

693 **Determination of intracellular ROS levels**

694 Single cell suspensions from mouse lungs were incubated with mouse FcR Blocking Reagent
695 for 5 min on ice and subsequently incubated with CellROX® Deep Red Reagent
696 (ThermoFisher Scientific, USA) for 30 min at 37°C following manufacturer's recommendations.
697 Next, cells were washed twice with MACS buffer, stained with DAPI and analysed by flow
698 cytometry.

699

700 **Quantitative proteomic analysis of Ly6G cells**

701 Neutrophils were FACS-sorted from single cell suspensions of metastatic lungs stained with
702 a conjugated anti-mouse Ly6G-APC antibody (3 samples from independent sorts). Ly6G cells
703 from the metastatic niche (Ch⁺) and the distal lung (Ch⁻) were digested into peptides using a
704 previously described protocol (<https://doi.org/10.1101/220343>) and analysed by Data
705 Independent Acquisition (DIA) mass spectrometry⁴¹ on a Orbitrap Fusion Lumos instrument
706 (ThermoFisher Scientific, USA). A hybrid spectral library was generated using the search
707 engine Pulsar in Spectronaut Professional+ (version 11.0.15038, Biognosys AG, Switzerland)
708 by combining Data Dependent Acquisition (DDA) runs obtained from a pooled sample of Ly6G
709 cells, and the DIA data. Data analysis and differential protein expression was performed using
710 Spectronaut Professional+. A detailed description of sample processing, data acquisition and
711 processing are provided upon request.

712

713 **Bioinformatic analysis**

714 **Bulk RNA sequencing:** the sequencing was performed on biological triplicates for each
715 condition generating approximately 35 million 76bp paired end reads. The RSEM package
716 (version 1.2.29)⁴² and Bowtie2 were used to align reads to the mouse mm10 transcriptome,
717 taken from known Gene reference table available at UCSC (<https://genome.ucsc.edu/>). For
718 RSEM, all parameters were run as default except "--forward-prob" which was set to "0.5".
719 Differential expression analysis was carried out with DESeq2 package⁴³ (version 1.12.4) within
720 R version 3.3.1 (<https://www.r-project.org/>). Genes were considered to be differentially
721 expressed if the adjusted p value was less than 0.05. Differentially expressed genes were
722 taken forward and their pathway and process enrichments were analysed using Metacore
723 (<https://portal.genego.com>). Hypergeometric test was used to determine statistical enriched
724 pathways and processes and the associated p-value corrected using Benjamini-Hochberg
725 method.

726 Gene Set Enrichment Analysis, GSEA, (version 2.2.3)^{44,45} was carried out using ranked gene
727 lists using the Wald statistic and the gene sets of C2 canonical pathways and C5 biological
728 processes. All parameters were kept as default except for enrichment statistic (classic) and
729 max size which was changed to 5000 respectively. Gene signatures with FDR q-value equal
730 or less than 0.05 were considered statistically significant. A weighted Kolmogorov–Smirnov-
731 like statistic was performed and the associated p-value corrected with Benjamini-Hochberg
732 method.

733 **Single cell RNA sequencing:** raw reads were initially processed by the Cell Ranger v2.1.1
734 pipeline, which deconvolved reads to their cell of origin using the UMI tags, aligned these to
735 the mm10 transcriptome using STAR (v2.5.1b) and reported cell-specific gene expression
736 count estimates. All subsequent analyses were performed in R-3.4.1 using the cellrangerRkit,
737 monocle and pheatmap packages. Genes were considered to be "expressed" if the estimated
738 (\log_{10}) count was at least 0.1. Primary filtering was then performed by removing from
739 consideration: genes expressed in fewer than 20 cells; cells expressing fewer than 50 genes;
740 cells for which the total yield (i.e. sum of expression across all genes) was more than 2
741 standard deviations from the mean across all cells in that sample; cells for which mitochondrial
742 genes made up greater than 10% of all expressed genes. PCA decomposition was performed
743 and, after consideration of the eigenvalue "elbow-plots", the first 25 components were used to
744 construct t-SNE plots for both samples. Niche cells expressing Epcam were subdivided into
745 those also expressing Cdh1 and those not expressing Cdh1. Other genes expressed in at
746 least 50% of cells in a given group were said to be co-expressed and the set of genes co-
747 expressed in one or more groups was presented as a heatmap, with the columns (cells)
748 clustered using the standard Euclidean hierarchical method.

749

750 **Methods References**

- 751 34. Guy, C. T., Cardiff, R. D. & Muller, W. J. Induction of mammary tumors by expression of
752 polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease.
753 *Mol. Cell. Biol.* **12**, 954–961 (1992).
- 754 35. Okabe, M., Ikawa, M., Kominami, K., Nakanishi, T. & Nishimune, Y. 'Green mice' as a
755 source of ubiquitous green cells. *FEBS Letters* **407**, 313–319 (1997).
- 756 36. Rock, J. R. *et al.* Multiple stromal populations contribute to pulmonary fibrosis without
757 evidence for epithelial to mesenchymal transition. *Proc Natl Acad Sci USA* **108**, E1475–
758 83 (2011).
- 759 37. Srinivas, S. *et al.* Cre reporter strains produced by targeted insertion of EYFP and ECFP
760 into the ROSA26 locus. *BMC Dev. Biol.* **1**, 4 (2001).
- 761 38. Rawlins, E. L. *et al.* The role of Scgb1a1+ Clara cells in the long-term maintenance and
762 repair of lung airway, but not alveolar, epithelium. *Cell Stem Cell* **4**, 525–534 (2009).
- 763 39. Lee, J.-H. *et al.* Anatomically and Functionally Distinct Lung Mesenchymal Populations
764 Marked by Lgr5 and Lgr6. *Cell* **170**, 1149–1156.e12 (2017).
- 765 40. Théry, C., Amigorena, S., Raposo, G. & Clayton, A. Isolation and characterization of
766 exosomes from cell culture supernatants and biological fluids. *Curr Protoc Cell Biol*
767 **Chapter 3**, Unit 3.22–3.22.29 (2006).
- 768 41. Bruderer, R. *et al.* Optimization of Experimental Parameters in Data-Independent Mass
769 Spectrometry Significantly Increases Depth and Reproducibility of Results. *Mol. Cell*
770 *Proteomics* **16**, 2296–2309 (2017).
- 771 42. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with
772 or without a reference genome. *BMC Bioinformatics* **12**, 323 (2011).
- 773 43. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion
774 for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
- 775 44. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for
776 interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 15545–
777 15550 (2005).
- 778 45. Mootha, V. K. *et al.* PGC-1alpha-responsive genes involved in oxidative phosphorylation
779 are coordinately downregulated in human diabetes. *Nat Genet* **34**, 267–273 (2003).

780

781

782 **Data availability**

783 The RNA sequencing datasets (GSE117930) and the single cell RNA sequencing datasets
784 (GEO13150) are deposited in the Gene Expression Omnibus (GEO, NCBI) repository. The
785 proteomic datasets are deposited in PRoteomics IDentifications (PRIDE) repository
786 (PXD010597).

787 **Supplementary Information** is available in the online version of the paper.

788

789 **Acknowledgments** We thank E. Sahai, P. Scaffidi (The Francis Crick Institute, London) and
790 V. Sanz-Moreno (Barts Cancer Institute, London) for scientific discussions, critical reading of
791 the manuscript and sharing cell lines and mouse strains. We thank M. Izquierdo (CSIC,
792 Madrid) for sharing the CD63-GFP plasmid. We are grateful to E. Nye and the pathologists G.
793 Stamp and E. Herbert from from the Experimental Histopathology Unit for histological
794 processing and analysis support. We thank J. Bee from the Biological Resources Unit at the
795 Francis Crick Institute for technical support with mice and mouse tissues. Thanks to R.
796 Goldstone and A. Edwards from the Advanced Sequencing Facility at the Francis Crick
797 Institute for technical support. We thank M. Llorian-Sopena from the Bioinformatics &
798 Biostatistics Unit at the Francis Crick Institute for helping with the RNA sequencing analysis.
799 We also thank the Flow Cytometry Unit at the Francis Crick Institute, particularly S. Purewal
800 and J. Cerveira, for invaluable technical help, and Cell Services Unit at the Francis Crick
801 Institute. We are grateful to C. Moore (The Francis Crick Institute, London) for intra-tracheal
802 injections. We are also grateful to I. Pshenichnaya, P. Humphreys, S. McCallum and
803 Cambridge Stem Cell Institute core facilities for technical assistance. We gratefully
804 acknowledge support from the FLI Core Facility Proteomics, which is a member of the Leibniz
805 Association and is financially supported by the Federal Government of Germany and the State
806 of Thuringia. This work was supported by the Francis Crick Institute which receives its core
807 funding from Cancer Research UK (FC001112), the UK Medical Research Council
808 (FC001112), and the Wellcome Trust (FC001112) and the European Research Council grant
809 (ERC CoG-H2020-725492); and by the Wellcome Trust – MRC Stem Cell Institute which
810 receives funding from the Sir Henry Dale Fellowship from Wellcome and the Royal Society
811 (107633/Z/15/Z) and the European Research Council Starting Grant (679411).

812

813 **Author Contribution** L.O. designed and performed most of the experiments, analysed and
814 interpreted the data and contributed to the manuscript preparation. E.N. assisted with data
815 collection, performed all the 3D-scaffold co-culture experiments, the *in vivo* Wisp1
816 experiments, the scRNA sequencing, interpreted and analysed the data and contributed to the
817 manuscript preparation. I.K. performed the qPCR analysis, some of the tissue IF staining and

818 analysed the data. A.M. and J.H.L. performed some of the tissue IF staining, all the lung
819 organoid experiments, interpreted and analysed the data. V.B. performed some of the tissue
820 IF staining. P.C. and S. H. performed bioinformatics analysis. I.H., J.K. and A.O. performed
821 the proteomic and analysed the data. E.G.G. helped with the collection of Ly6G⁺ cells for
822 proteomics. G.M. performed the 3D-scaffold co-culture to analyse CD104⁺ cells. A.W. and
823 L.C. performed the electron microscopy experiments. E.H. and V.S. provided human samples.
824 L.O., E.N., I.K., V.B. and J.H.L., critically reviewed the manuscript. J.H.L., supervised the lung
825 organoid experiments. I.M. designed and supervised the study, interpreted the data and wrote
826 the manuscript.

827

828 **Author Information** Reprints and permissions information is available at
829 www.nature.com/reprints. The authors declare no competing financial interests. All animal
830 work was conducted under UK Home Office regulations, project licenses P83B37B3C and
831 PC7F8AE82. Correspondence and requests for materials should be addressed to: Ilaria
832 Malanchi (Ilaria.Malanchi@crick.ac.uk) and Joo-Hyeon Lee (jhl62@cam.ac.uk).

833

834 **Extended Data Figure Legends**

835 **Extended Data Figure 1 - Cherry-niche *in vitro***

836 **a**, sLP-mCherry design. **b**, Fluorescence images of Labelling-4T1 cells post-thawing. Scale
837 bar 10 μ m. **c**, Representative FACS plot of Labelling-4T1 cells. **d**, *In vitro* cultures of the
838 indicated cell types with Labelling-4T1 cell conditioned media (LCM): culture scheme and
839 representative fluorescence images of HC11 (murine mammary epithelial cells) and hNLF
840 (human normal lung fibroblasts) with LCM (scale bar 10 μ m). **e**, FACS plots of 4T1, HC11,
841 RAW264.7 (murine macrophages), hNLF, murine breast Carcinoma Associated Fibroblasts
842 (CAF) cultured with LCM. **f**, FACS analysis of 293T cells cultured with LCM, at different time-
843 points after LCM removal (black dots); white dots show the theoretical decrease considering
844 the cell proliferation rate only (the amount of 293T cells mCherry labelled after 24h incubation
845 with LCM was set to 100%). **g**, Representative fluorescence image of 4T1-CD63GFP cells
846 cultured with LCM. Scale bars: main 5 μ m, inset 1 μ m. **h**, Representative Correlative Light and
847 Electron Microscopy (CLEM) of Labelling-4T1 cells re-up-taking sLP-mCherry (n=5 different
848 cells analysed): upper-left panel shows bright-field image overlaid mCherry IF (~700nm optical
849 section); lower-left panel shows EM of same cell (~70nm section thickness); large central
850 panel shows best approximation of IF/bright-field/EM overlay (scale bar 5 μ m); right panels
851 show EM insets from indicated areas in the large central panel (black arrows point at vesicular
852 structures containing the mCherry, scale bar 1 μ m). **i**, **j**, Analysis of *in vitro* labelling potential

853 of soluble fraction and extracellular vesicles (EVs) isolated from LCM by FACS: (i) schematic
854 representation of LCM fractionation; (j) HC11 cells cultured with either LCM, soluble fraction
855 after EVs depletion (soluble) or purified EVs. **k**, ImageStream analysis of Cherry⁺ EVs in LCM
856 (16% of total EVs are Cherry⁺). Data are representative one of three (b), ten (c), two (d, e-g,
857 j, k) independent experiments. See Source Data.

858

859 **Extended Data Figure 2 - Cherry-niche *in vivo*.**

860 **a, b**, Distance of labelled cells within metastases: (a) representative fluorescence images
861 (lines measure the maximum distance of labelled cells (mCherry) from Labelling-4T1 cells
862 (mCherry/GFP); scale bar 50 μ m); (b) quantification of labelling distance in micro-metastases
863 (n=11) and macro-metastases (n=4). **c**, Correlation between the percentage of mCherry
864 labelled niche cells and the percentage of cancer cells in metastatic lungs analysed by FACS:
865 only low number of cancer cells (left, n=14 mice) and all cancer cell frequencies (right, n=31
866 mice). Statistical analysis by Pearson correlation. **d-f**, CD45⁺ cell frequency on live cells in
867 distal lung, Cherry-niche and naïve lungs (collected from mice which were not injected) by
868 FACS: (d) Balb/c mice injected with Labelling-4T1 cells (n=5 per group); (e) Balb/c mice
869 injected with Labelling-HC11 cells (n=4); (f) Rag1ko mice injected with Labelling-4T1 cells
870 (n=10). Statistical analysis by paired two-tailed t-test. Data are represented as mean \pm SEM.
871 See Source Data.

872

873 **Extended Data Figure 3 - Cherry-niche neutrophils increase ROS production.**

874 **a, b**, (a) CD11b⁺ and (b) Ly6G⁺ cell frequencies on live cells in distal lung and Cherry-niche by
875 FACS (n=9 per group). **c**, Enriched processes by MetaCore analysis and GSEA on proteomic
876 data (by comparing Cherry-niche (n=3) and distal lung (n=3) neutrophils; Cherry-niche
877 dominant proteins obtained by using WebGestalt (<http://www.webgestalt.org/option.php>). **d**,
878 PCA of proteins found in unlabelled or Cherry-niche neutrophils (n=3, each with 10 mice, small
879 circles; large circles represent the average of the triplicates). **e**, Representative FACS plot and
880 **f**, scatter plot of intrinsic ROS in Ly6G⁺ cells (n=6). **g**, GFP signal quantification of 3D co-
881 culture with MMTV-PyMT-GFP⁺ cancer cells, Ly6G⁺ MACS-sorted cells from either naïve or
882 metastatic lungs with or without the ROS inhibitor TEMPO (n=3, each with 3 wells). Data is
883 normalised to cancer cell growth (Statistical analysis on biological replicates). **h**,
884 Representative cancer cell growth on the scaffold (from 14 independent experiments):
885 integrated density of the GFP signal measured on the scaffold using ImageJ and the
886 corresponding fluorescent image of GFP⁺ cancer cell growth (scale bar 400 μ m). Statistical
887 analysis by paired two-tailed t-test (a, b, f), hypergeometric test with Benjamini-Hochberg
888 correction (c, Metacore), weighted Kolmogorov–Smirnov-like statistic with Benjamini-

889 Hochberg correction (c, GSEA) and Two-way ANOVA (g). Data represented as mean \pm SD (f)
890 and \pm SEM (g). See Source Data.

891

892 **Extended Data Figure 4 - RNA sequencing of non-immune Cherry-niche cells.**

893 **a, b**, GSEA on Cherry-niche upregulated genes: (a) percentage of correlating processes
894 related to the indicated activity and (b) specific signalling pathways (indicated by the * in (a)
895 either at early or late time point). **c**, MetaCore analysis on genes differentially expressed from
896 RNA-seq data, comparing early (n=3) or late (n=3) Cherry+ samples vs the respective Cherry-
897 (see Fig.3a, b). Statistical analysis by hypergeometric test with Benjamini-Hochberg
898 correction.

899

900 **Extended Data Figure 5 - Wisp1 supports metastatic growth.**

901 **a, b**, Representative IF images of lung metastatic tissues (n=2 mice) stained with GFP (green)
902 to detect Labelling-4T1 cells, WISP1 (red) and DAPI (blue) showing distal lung and metastatic
903 areas, scale bar 50 μ m; (b) a representative image showing the enrichment of Wisp1+ cells
904 within lung metastasis including niche cells (white arrows); scale bar 50 μ m. **c-e**, Anti-WISP1
905 blocking antibody treatment *in vivo*: (c) experimental design (IT, intratracheal injection; IP,
906 intraperitoneal injection); (d) metastatic outcome measured as the percentage of lung area
907 covered by metastases (quantification was performed on two lung levels 100 μ m apart); (e)
908 representative H&E images (n=5 mice each group; black arrows show metastatic foci); scale
909 bar 500 μ m. Two experiments with lower overall metastatic frequency are quantified in Figure
910 3e. Statistical analysis by Two-way Anova (d). Data represented as mean \pm SEM. See Source
911 Data.

912

913 **Extended Data Figure 6 – Lung pneumocytes react to cancer cells in human breast**
914 **pulmonary metastases.**

915 **a-c**, Histology on human breast tumour lung metastases sections: (a) representative image of
916 distal lung (scale bar 100 μ m) and (b) image from the tumour-lung interface showing the
917 pneumocyte marker Thyroid Transcription Factor 1 (TTF1) expression (scale bar 50 μ m); (c)
918 representative histology images from metastatic border (scale bar 100 μ m). **d-f**, Alveolar cell
919 proliferation in human breast tumour lung metastases analysed by IF: representative images
920 from (d) distal lung and (e) metastatic border showing TTF1 (red), Ki67 (green) and DAPI
921 (blue), scale bars: main 100 μ m, inset 50 μ m; (f) quantification shown on a Tukey plot: box from
922 the 25th to 75th percentiles, the bar is the median and the whiskers from smallest to largest
923 value. Statistical analysis by paired two-tailed t-test. Tissue sections from n=4 independent
924 patients were analysed. See Source Data.

925

926 **Extended Data Figure 7 - Epithelial cells support cancer cell growth *ex vivo*.**

927 **a**, MMTV-PyMT-GFP⁺ cancer cell proliferation in 2D co-culture with MACS-sorted Epcam⁺ and
928 Ly6G⁺ cells stained with EdU and analysed by FACS (n=3 independent experiments). Data
929 normalised to cancer cell proliferation. **b-d**, 3D co-culture of MMTV-PyMT-GFP⁺ cancer cell
930 with MACS-sorted Epcam⁺ and Ly6G⁺ cells: (b) co-culture scheme; (c) representative images
931 from 4 independent experiments (day 4, scale bar 400µm); (d) GFP signal quantification. Data
932 normalised to cancer cell growth (n=4 independent experiments (dots), each with 3-4 technical
933 replicates). Statistical analysis on biological replicates by one sample two-tailed t-test (a) and
934 Two-way ANOVA (d). Data are represented as mean ±SEM. See Source Data.

935

936 **Extended Data Figure 8 - scRNA-seq analysis reveals different sub-pools of stromal
937 cells in the niche.**

938 **a**, tSNE plots of CD45⁻ cells isolated from distal lung (n=1996) or Cherry-niche (n=1473) after
939 scRNA-seq analysis: the CAFs are coloured based on the expression levels of the indicated
940 genes. **b**, tSNE niche plots (a), where each plot shows in red the cells expressing the indicated
941 stromal marker. **c**, MetaCore pathway enrichment analysis using the list of genes detected in
942 at least 50% of the indicated marker defined cells (n=66 Thy1⁺ cells, n=175 Pdgfrb1⁺ cells,
943 n=322 Pdgfra⁺ cells, n=330 Acta2⁺ cells, n=25 Lgr6⁺ cells). Statistical analysis by
944 hypergeometric test with Benjamini-Hochberg correction.

945

946 **Extended Data Figure 9 - Cherry-niche epithelial cells are enriched for stem cell
947 markers.**

948 **a**, Representative FACS plots showing Lin⁻ (CD45⁻CD31⁻Ter119⁻) cells in distal lung and
949 Cherry-niche from Labelling-4T1 injected mice (quantification in Fig.4i). **b**, **c**, Scatter plots
950 showing FACS quantification of Epcam⁺Sca1⁺ cell frequency on Lin⁻ (CD45⁻CD31⁻Ter119⁻)
951 cells in distal lung and Cherry-niche with (b) Labelling-RENCA (n=5) and (c) Labelling-CT26
952 (n=4). **d-f**, (d) Scatter plot of CD49f⁺CD104⁺ cell frequency on Lin⁻ (CD45⁻CD31⁻Ter119⁻) cells
953 in distal lung and Cherry-niche by FACS (n=5); (e) representative FACS plots; (f)
954 representative IF image of FACS-sorted Cherry-niche CD49f⁺CD104⁺ cells using E-cadherin
955 (green) and DAPI (blue); scale bar 20µm. **g-i**, 3D co-culture of MMTV-PyMT-GFP⁺ cancer
956 cells with MACS-sorted Epcam⁺ cells: (g) quantification of integrin β4 (CD104) expression on
957 Epcam⁺ cells; (h) number of CD104⁺ cells proximal to cancer cells (n=4 from three
958 independent sorts); (i) representative IF image from the co-culture stained with CD104 (red);
959 GFP⁺ cancer cells (green) and DAPI (blue); scale bar 20µm. Statistical analysis on biological

960 replicates (g-h) by paired two-tailed t-test (b-d, g). Data represented as mean \pm SEM. See
961 Source Data.

962

963 **Extended Data Figure 10 - Cancer cells change lung epithelial cell lineage commitment**
964 ***ex-vivo***.

965 **a**, Representative IF images of lung metastatic sections (n=3 mice) co-stained with airway
966 markers, either (a) Scgb1a1 (white) or (b) Sox2 (white), Cherry (red) and DAPI (blue); scale
967 bar 100 μ m. **b, c**, Lung organoids with Epcam⁺ FACS-sorted cells in co-culture with either lung
968 stromal CD31⁺ cells or MLg fibroblasts alone or in presence 4T1-GFP cells from metastatic
969 lungs in the lower chamber: (b) quantification and (c) representative bright-field images of
970 organoids, scale bar 150 μ m. **d-e**, Lung organoids with Scgb1a1-CreERT2 lineage cells with
971 or without 4T1-GFP: quantification (d) and representative bright-field pictures (e), scale bar
972 150 μ m. **f**, Representative staining of lineage cells in metastatic lungs from Scgb1a1-CreERT2
973 mice injected with MMTV-PyMT cancer cells. Scale bars: main 50 μ m, apart from the first 2
974 panels where it's 200 μ m (inset 25 μ m). Data generated with sorted Epcam (b) or club-lineage
975 cells (d) and represented as cumulative percentage indicating the mean \pm SD of three co-
976 cultures per sorting. Statistical analysis by two-tailed t-test (b, d), for original non-cumulative
977 values see accompanying Source Data. Images are representative of three organoid cultures
978 (c, e). See Source Data.

979

980